Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Exp Med. Nov 20, 2014; 4(4): 58-67
Published online Nov 20, 2014. doi: 10.5493/wjem.v4.i4.58
Published online Nov 20, 2014. doi: 10.5493/wjem.v4.i4.58
Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current status
Antonia Digklia, Department of Medical Oncology, University Hospital of Lausanne, 1011 Lausanne, Switzerland
Ioannis A Voutsadakis, Division of Medical Oncology, Department of Internal Medicine, Sault Area Hospital, Sault Sainte Marie, Ontario, ON P6B 0A8, Canada
Ioannis A Voutsadakis, Division of Clinical Sciences, Northern Ontario School of Medicine, Sudbury, Ontario, ON P6B 0A8, Canada
Author contributions: Both authors contributed to this paper.
Correspondence to: Ioannis A Voutsadakis, MD, PhD, Division of Clinical Sciences, Northern Ontario School of Medicine, 750 Great Northern Road, Sault Ste Marie, Sudbury, Ontario, ON P6B 0A8, Canada. ivoutsadakis@yahoo.com
Telephone: +1-705-7593434 Fax: +1-705-7593815
Received: June 11, 2014
Revised: July 16, 2014
Accepted: September 6, 2014
Published online: November 20, 2014
Revised: July 16, 2014
Accepted: September 6, 2014
Published online: November 20, 2014
Core Tip
Core tip: Metronomic chemotherapy has the potential to reduce the toxicity of chemotherapy administered with conventional schedules. In addition, understanding of the importance of angiogenesis in the mechanism of action of metronomic schedules provides a rational to combine this type of administration with targeted agents against the vascular endothelial growth factor signaling pathway.